Trial Profile

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RBX 2660 (Primary)
Indications Clostridium difficile infections
Focus Adverse reactions; Registrational
Acronyms CDI-SCOPE
Sponsors Ferring Pharmaceuticals

Most Recent Events

05 May 2025 According to a Ferring Pharmaceuticals media release, Dr. Paul Feuerstadt is lead investigator of CDI-SCOPE trial.
05 May 2025 According to a Ferring Pharmaceuticals media release, data from the trial were presented at at Digestive Disease Week 2025 (DDW2025) from May 3-6 in San Diego, CA.
05 May 2025 Results presented in the Ferring Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com